moxonidine
Sign in to saveAlso known as Nucynt, BDF5896, Norcynt, BE5895, Cynt, (2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid
Moxonidine (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals (acquired by Abbott in 2009) under the bran
Research
676 papers- Moxonidine: some controversy.Expert opinion on pharmacotherapy · 2001
- Moxonidine for hypertension.Drug and therapeutics bulletin · 1997
- Moxonidine: a review.Journal of human hypertension · 1997
- Pharmacology of moxonidine, an I1-imidazoline receptor agonist.Journal of cardiovascular pharmacology · 1996
- Clinical experience with moxonidine.Cardiovascular drugs and therapy · 1994
via PubMed
Wikidata facts
- Mass
- 241.073038
Show 4 more facts
- chemical formula
- C₉H₁₂ClN₅O
- canonical SMILES
- CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
- defined daily dose
- 0.3
- Commons category
- Moxonidine
via Wikidata · CC0
~4 min read
Article
10 sectionsContents
- Mechanism of action
- Pharmacodynamic properties
- Effects on insulin resistance
- Contraindications
- Adverse effects
- Safety
- Drug interactions
- See also
- References
- External links
Moxonidine (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction. It is also a growth hormone releaser. It is manufactured by Solvay Pharmaceuticals (acquired by Abbott in 2009) under the brand name Physiotens and Moxon.
==Mechanism of action== Moxonidine is a selective agonist at the imidazoline receptor subtype 1 (I1). This receptor subtype is found in both the rostral ventro-lateral pressor and ventromedial depressor areas of the medulla oblongata. Moxonidine therefore causes a decrease in sympathetic nervous system activity and, therefore, a decrease in blood pressure.